Omitama

Researchers are studying the use of REKOVELLE Pen, a subcutaneous injection drug, for controlled ovarian stimulation in women undergoing assisted reproductive technologies like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The goal is to develop multiple eggs for use in these fertility treatments. This survey collects real-world data on the general use of this drug during such procedures. Participants receive REKOVELLE injections at doses of 12 mcg, 36 mcg, or 72 mcg to stimulate the ovaries as part of their assisted reproduction treatment. The survey observes the drug’s use in routine clinical practice without altering the treatment schedule or doses. The study covers the period from drug administration through either one week after egg collection if no embryo transfer occurs, or six weeks after embryo transfer if performed. During the survey, participants are monitored for adverse events from when they start the REKOVELLE injections until the specified follow-up period after egg collection or embryo transfer. Data collection focuses on safety outcomes and general drug use under everyday medical conditions. Participants’ involvement includes consenting to data sharing without additional interventions, reflecting typical treatment experience.